Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Processa Pharmaceuticals Inc
(NQ:
PCSA
)
1.312
-0.018 (-1.38%)
Streaming Delayed Price
Updated: 9:44 AM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Processa Pharmaceuticals Inc
< Previous
1
2
3
Next >
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
October 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
September 03, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
August 28, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
August 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
July 30, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
July 17, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
June 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
May 06, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
April 30, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
April 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
Exposures
Product Safety
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
March 28, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
March 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
February 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
Exposures
Pension
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
January 26, 2024
Via
Investor Brand Network
Exposures
Product Safety
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
January 26, 2024
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
January 25, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
January 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
January 18, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
January 03, 2024
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
December 19, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Gains Helpful Guidance on Overall Design of NGC-Cap Phase 2 Study
December 13, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in December MedInvest Oncology Investor Conference
November 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Shareholder Letter
November 29, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Unexpected Passing of Board Member
November 14, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming Orphan Drugs and Rare Diseases Global Congress
November 09, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Creates Advisory Board, Names Renowned Experts as Members
November 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming ThinkEquity Conference
October 13, 2023
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.